Can infections cause Alzheimer's disease?

Epidemiologic Reviews

Volumn 35, Issue 1, 2013, Pages 161-180

  Mawanda, Francis ^a   Wallace, Robert ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Alzheimer disease; bacteria; dementia; infection; neurodegenerative diseases; prions; sepsis; viruses

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; BETA SECRETASE; DOXYCYCLINE; GAMMA SECRETASE; GLYCOPROTEIN B; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 6; PRION PROTEIN; RIFAMPICIN; TAU PROTEIN; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BORRELIA BURGDORFERI; BRAIN INFECTION; CARBOXY TERMINAL SEQUENCE; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CREUTZFELDT JAKOB DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DOWN SYNDROME; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; ETHNICITY; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENITAL HERPES; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; KURU; LEPROSY; LEWY BODY; LYME DISEASE; MEDLINE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEPSIS; SEROPREVALENCE; SOCIAL STATUS; SOUTHERN BLOTTING; SUBACUTE SCLEROSING PANENCEPHALITIS; SYSTEMATIC REVIEW; TUBERCULOSIS; VIRUS TRANSMISSION; CAUSALITY; CHLAMYDOPHILA INFECTIONS; HELICOBACTER INFECTIONS; INFECTION;

ALZHEIMER DISEASE; CAUSALITY; CHLAMYDOPHILA INFECTIONS; HELICOBACTER INFECTIONS; HERPES SIMPLEX; HUMANS; INFECTION; LYME DISEASE;

EID: 84874488436     PISSN: 0193936X     EISSN: 14786729     Source Type: Journal    
DOI: 10.1093/epirev/mxs007     Document Type: Article

References (248)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (4th ed., text rev.). Washington, DC: American Psychiatric Association; 2000.
2. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
3. Grady CL, Haxby JV, Horwitz B, et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol. 1988;10(5):576-596.
4. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
5. Hutton M, Busfield F, Wragg M, et al. Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. Neuroreport. 1996;7(3):801-805.
6. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349(6311):704-706.
7. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269(5226):973- 977.
8. Antonell A, Balasa M, Oliva R, et al. A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. Neurosci Lett. 2011;496(1):40-42.
9. Campion D, Flaman JM, Brice A, et al. Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet. 1995;4(12):2373-2377.
10. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer's disease incidence: a prospective cohort study. Arch Neurol. 2002;59(11):1737-1746.
11. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham study. Neurology. 1993;43(3): 515-519.
12. Stern Y, Gurland B, Tatemichi TK, et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994;271(13):1004- 1010.
13. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education: the Rotterdam study. BMJ. 1995;310(6985): 970-973.
14. Fleminger S, Oliver DL, Lovestone S, et al. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry. 2003;74(7):857-862.
15. Mortimer JA, van Duijn CM, Chandra V, et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20(suppl 2): S28-S35.
16. Plassman BL, Havlik RJ, Steffens DC, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology. 2000;55(8): 1158-1166.
17. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322(7300): 1447-1451.
18. Chiang CJ, Yip PK, Wu SC, et al. Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan. Am J Geriatr Psychiatry. 2007;15(9):762-771.
19. Profenno LA, Porsteinsson AP, Faraone SV, et al. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010; 67(6):505-512.
20. Xu WL, von Strauss E, Qiu CX, et al. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia. 2009;52(6):1031-1039.
21. Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology. 1997;48(1):139-147.
22. Borgaonkar DS, Schmidt LC, Martin SE, et al. Linkage of late-onset Alzheimer's disease with apolipoprotein E type 4 on chromosome 19 [letter]. Lancet. 1993;342(8871):625.
23. Brousseau T, Legrain S, Berr C, et al. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology. 1994;44(2): 42-344.
24. Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007;68(4):613-618.
25. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123): 921-923.
26. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease. A meta-analysis. APOE and Alzheimer Disease Meta-analysis Consortium. JAMA. 1997;278(16):1349-1356.
27. Liddell M, Williams J, Bayer A, et al. Confirmation of association between the e4 allele of apolipoprotein E and Alzheimer's disease. J Med Genet. 1994;31(3):197-200.
28. Lucotte G, Visvikis S, Leininger-Muler B, et al. Association of apolipoprotein E allele epsilon 4 with late-onset sporadic Alzheimer's disease. Am J Med Genet. 1994;54(3):286-288.
29. Rondeau V. A review of epidemiologic studies on aluminum and silica in relation to Alzheimer's disease and associated disorders. Rev Environ Health. 2002;17(2):107-121.
30. Chang CC, Zhao Y, Lee CW, et al. Smoking, death, and Alzheimer disease: a case of competing risks. Alzheimer Dis Assoc Disord. 2012;26(4):300-306.
31. Jamieson GA, Maitland NJ, Wilcock GK, et al. Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J Pathol. 1992;167(4):365-368.
32. Letenneur L, Pérès K, Fleury H, et al. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. PLoS One. 2008; 3(11):e3637. (doi:10.1371/ journal.pone.0003637).
33. Balin BJ, Gerard HC, Arking EJ, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol. 1998;187(1):23-42.
34. Gerard HC, Dreses-Werringloer U, Wildt KS, et al. Chlamy-dophila (chlamydia)pneumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol. 2006;48(3):355-366.
35. Paradowski B, Jaremko M, Dobosz T, et al. Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia. J Neurol. 2007;254(2):154-159.
36. Kountouras J, Boziki M, Gavalas E, et al. Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer's disease. Int JNeurosci. 2009;119(6):765-777.
37. Malaguarnera M, Bella R, Alagona G, et al. Helicobacter pylori and Alzheimer's disease: a possible link. Eur J Intern Med. 2004;15(6):381-386.
38. Miklossy J. Alzheimer's disease-a spirochetosis? Neuroreport. 1993;4(7):841-848.
39. Carter CJ. Alzheimer's disease: a pathogenetic autoimmune disorder caused by herpes simplex in a gene-dependent manner. Int J Alzheimers Dis. 2010;2010:140539. (doi:10.4061/2010/140539).
40. Braak E, Braak H, Mandelkow EM. A sequence of cytoskel-eton changes related to the formation of neurofibrillary tangles and neutropil threads. Acta Neuropathol. 1994; 87(6):554-567.
41. Togo T, Akiyama H, Iseki E, et al. Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions. Acta Neuropathol. 2004;107(6): 504-508.
42. Bancher C, Brunner C, Lassmann H, et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1989;477(1-2):90-99.
43. Gomez-Ramos P, Moran MA. Ultrastructural aspects of neu-rofibrillary tangle formation in aging and Alzheimer's disease. Microsc Res Tech. 1998;43(1):49-58.
44. Zhang YW, Thompson R, Zhang H, et al. APP processing in Alzheimer's disease. Mol Brain. 2011;4:3. (doi:10.1186/1756-6606-4-3).
45. Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener. 2011;6(1): 27. (doi:10.1186/1750-1326-6-27).
46. Ikeda K, Akiyama H, Kondo H, et al. Numerous glial fibril-lary tangles in oligodendroglia in cases of subacute scleros-ing panencephalitis with neurofibrillary tangles. Neurosci Lett. 1995;194(1-2):133-135.
47. Mandybur TI. The distribution of Alzheimer's neurofibril-lary tangles and gliosis in chronic subacute sclerosing pan-encephalitis. Acta Neuropathol. 1990;80(3):307-310.
48. Kueh Y, Devathasan G. Amyloid neuropathy in a woman with tabes dorsalis [letter]. N Engl J Med. 1984;310(12): 789.
49. Liberski PP. Transmissible cerebral amyloidoses as a model for Alzheimer's disease. An ultrastructural perspective. Mol Neurobiol. 1994;8(1):67-77.
50. Kobayashi A, Arima K, Ogawa M, et al. Plaque-type deposition of prion protein in the damaged white matter of sporadic Creutzfeldt-Jakob disease MM1 patients. Acta Neuropathol. 2008;116(5):561-566.
51. Sikorska B, Liberski PP, Sobow T, et al. Ultrastructural study of florid plaques in variant Creutzfeldt-Jakob disease: a comparison with amyloid plaques in kuru, sporadic Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease. Neuropathol Appl Neurobiol. 2009; 35(1):46-59.
52. de Beer FC, Nel AE, Gie RP, et al. Serum amyloid A protein and C-reactive protein levels in pulmonary tuberculosis: relationship to amyloidosis. Thorax. 1984;39(3):196-200.
53. Looi LM, Jayalakshim P, Lim KJ, et al. An immunohisto-chemical and morphological study of amyloidosis complicating leprosy in Malaysian patients. Ann Acad Med Singapore. 1988;17(4):573-578.
54. Looi LM. The pattern of amyloidosis in Malaysia. Malays J Pathol. 1994;16(1):11-13.
55. Röcken C, Radun D, Glasbrenner B, et al. Generalized AA-amyloidosis in a 58-year-old Caucasian woman with an 18-month history of gastrointestinal tuberculosis. Virchows Arch. 1999;434(1):95-100.
56. Wangel AG, Wegelius O, Dyrting AE. A family study of leprosy: subcutaneous amyloid deposits and humoral immune responses. Int J Lepr Other Mycobact Dis. 1982; 50(1):47-55.
57. Tank SJ, Chima RS, Shah V, et al. Renal amyloidosis following tuberculosis. Indian J Pediatr. 2000;67(9):679-681.
58. Urban BA, Fishman EK, Goldman SM, et al. CT evaluation of amyloidosis: spectrum of disease. Radiographics. 1993;13(6):1295-1308.
59. Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One. 2010;5(3):e9505. (doi:10.1371/journal. pone.0009505).
60. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4): 239-259.
61. Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011; 70(11):960-969.
62. Thal DR, Rüb U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-1800.
63. Satpute-Krishnan P, DeGiorgis JA, Bearer EL. Fast antero-grade transport of herpes simplex virus: role for the amyloid precursor protein of Alzheimer's disease. Aging Cell. 2003; 2(6):305-318.
64. Shipley SJ, Parkin ET, Itzhaki RF, et al. Herpes simplex virus interferes with amyloid precursor protein processing. BMC Microbiol. 2005;5:48. (doi:10.1186/1471-2180-5-48).
65. Kristensson K, Vahlne A, Persson LA, et al. Neural spread of herpes simplex virus types 1 and 2 in mice after corneal or subcutaneous (footpad) inoculation. J Neurol Sci. 1978;35(2-3):331-340.
66. Wisner TW, Sugimoto K, Howard PW, et al. Anterograde transport of herpes simplex virus capsids in neurons by both separate and married mechanisms. J Virol. 2011;85(12): 5919-5928.
67. Hill JM, Steiner I, Matthews KE, et al. Statins lower the risk of developing Alzheimer's disease by limiting lipid raft endocytosis and decreasing the neuronal spread of herpes simplex virus type 1. Med Hypotheses. 2005;64(1):53-58.
68. Hill J, Gebhardt B, Azcuy A, et al. Can a herpes simplex virus type 1 neuroinvasive score be correlated to other risk factors in Alzheimer's disease? [abstract]. Neurobiol Aging. 2004;25:S399.
69. MacDonald AB. Alzheimer's disease Braak Stage progressions: reexamined and redefined as Borrelia infection transmission through neural circuits. Med Hypotheses. 2007; 68(5):1059-1064.
70. MacDonald AB. Alzheimer's neuroborreliosis with trans-synaptic spread of infection and neurofibrillary tangles derived from intraneuronal spirochetes. Med Hypotheses. 2007;68(4):822-825.
71. Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318(1):121-134.
72. Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7(2):e31302. (doi:10.1371/journal.pone.0031302).
73. Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci. 2006;24(2-3):167-176.
74. Holmes C, Butchart J. Systemic inflammation and Alzheimer's disease. Biochem Soc Trans. 2011;39(4): 898-901.
75. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21(3):383-421.
76. Cojocaru IM, Cojocaru M, Miu G, et al. Study of interleu-kin-6 production in Alzheimer's disease. Rom J Intern Med. 2011;49(1):55-58.
77. Sy M, Kitazawa M, Medeiros R, et al. Inflammation induced by infection potentiates tau pathological features in trans-genic mice. Am J Pathol. 2011;178(6):2811-2822.
78. Kahn MS, Kranjac D, Alonzo CA, et al. Prolonged elevation in hippocampal Aβ and cognitive deficits following repeated endotoxin exposure in the mouse. Behav Brain Res. 2012;229(1):176-184.
79. Bamberger ME, Landreth GE. Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease. Microsc Res Tech. 2001;54(2):59-70.
80. Nagele RG, Clifford PM, Siu G, et al. Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta(1-42) deposition. J Alzheimers Dis. 2011;25(4):605-622.
81. Levin EC, Acharya NK, Han M, et al. Brain-reactive autoan-tibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res. 2010;1345:221-232.
82. Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotox-icity: implications for disease pathogenesis and vaccine development. Neuromolecular Med. 2003;3(1):29-39.
83. Ounanian A, Guilbert B, Renversez JC, et al. Antibodies to viral antigens, xenoantigens, and autoantigens in Alzheimer's disease. J Clin Lab Anal. 1990;4(5):367-375.
84. Bonotis K, Krikki E, Holeva V, et al. Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol. 2008;193(1-2):183-187.
85. Richartz-Salzburger E, Batra A, Stransky E, et al. Altered lymphocyte distribution in Alzheimer's disease. J Psychiatr Res. 2007;41(1-2):174-178.
86. Schindowski K, Eckert A, Peters J, et al. Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immu-notherapy. Neuromolecular Med. 2007;9(4):340-354.
87. Speciale L, Calabrese E, Saresella M, et al. Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol Aging. 2007;28(8):1163-1169.
88. Arduino PG, Porter SR. Herpes simplex virus type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med. 2008;37(2):107-121.
89. Mahalingam R, Wellish MC, Dueland AN, et al. Localization of herpes simplex virus and varicella zoster virus DNA in human ganglia. Ann Neurol. 1992;31(4): 444-448.
90. Jakob NJ, Lenhard T, Schnitzler P, et al. Herpes simplex virus encephalitis despite normal cell count in the cerebro-spinal fluid. Crit Care Med. 2012;40(4):1304-1308.
91. Liedtke W, Opalka B, Zimmermann CW, et al. Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. J Neurol Sci. 1993;116(1):6-11.
92. Brookmeyer R, Evans DA, Hebert L, et al. National estimates of the prevalence of Alzheimer's disease in the united states. Alzheimers Dement. 2011;7(1):61-73.
93. Bullido MJ, Martinez-Garcia A, Tenorio R, et al. Double stranded RNA activated EIF2 alpha kinase (EIF2AK2; PKR) is associated with Alzheimer's disease. Neurobiol Aging. 2008;29(8):1160-1166.
94. Carter CJ. Interactions between the products of the herpes simplex genome and Alzheimer's disease susceptibility genes: relevance to pathological- signalling cascades. Neurochem Int. 2008;52(6):920-934.
95. Lin WR, Shang D, Itzhaki RF. Neurotropic viruses and Alzheimer disease. Interaction of herpes simplex type 1 virus and apolipoprotein E in the etiology of the disease. Mol Chem Neuropathol. 1996;28(1-3):135-141.
96. Itzhaki RF, Lin WR, Shang D, et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet. 1997;349(9047):241-244.
97. Beffert U, Bertrand P, Champagne D, et al. HSV-1 in brain and risk of Alzheimer's disease [letter]. Lancet. 1998; 351(9112):1330.
98. Feart C, Helmer C, Fleury H, et al. Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels. PLoS One. 2011;6(12):e29480. (doi:10.1371/journal. pone.0029480).
99. Deatly AM, Haase AT, Fewster PH, et al. Human herpes virus infections and Alzheimer's disease. Neuropathol Appl Neurobiol. 1990;16(3):213-223.
100. Sequiera LW, Jennings LC, Carrasco LH, et al. Detection of herpes-simplex viral genome in brain tissue. Lancet. 1979; 2(8143):609-612.
101. Mori I, Yokochi T, Koide N, et al. PCR search for the herpes simplex virus type 1 genome in brain sections of patients with familial Alzheimer's disease [letter]. J Clin Microbiol. 2004;42(2):936-937.
102. Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol. 2009;217(1):131-138.
103. Cribbs DH, Azizeh BY, Cotman CW, et al. Fibril formation and neurotoxicity by a herpes simplex virus glycoprotein B fragment with homology to the Alzheimer's A beta peptide. Biochemistry. 2000;39(20):5988-5994.
104. Cheng S-B, Ferland P, Webster P, et al. Herpes simplex virus dances with amyloid precursor protein while exiting the cell. PLoS One. 2011;6(3):e17966. (doi:10.1371/journal. pone.0017966).
105. Santana S, Recuero M, Bullido MJ, et al. Herpes simplex virus type I induces the accumulation of intracellular beta-amyloid in autophagic compartments and the inhibition of the non-amyloidogenic pathway in human neuroblastoma cells. Neurobiol Aging. 2012;33(2):430.e19-430.e33.
106. De Chiara G, Marcocci ME, Civitelli L, et al. APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells. PLoS One. 2010;5(11):e13989. (doi:10.1371/journal. pone.0013989).
107. Wozniak MA, Itzhaki RF, Shipley SJ, et al. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett. 2007;429(2-3): 95-100.
108. Zambrano A, Solis L, Salvadores N, et al. Neuronal cyto-skeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1. J Alzheimers Dis. 2008;14(3):259-269.
109. Álvarez G, Aldudo J, Alonso M, et al. Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J Neurosci Res. 2012;90(5):1020-1029.
110. Wozniak MA, Frost AL, Itzhaki RF. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis. 2009;16(2):341-350.
111. Middleton PJ, Petric M, Kozak M, et al. Herpes-simplex viral genome and senile and presenile dementias of Alzheimer and Pick [letter]. Lancet. 1980;1(8176):1038.
112. Taylor GR, Crow TJ, Markakis DA, et al. Herpes simplex virus and Alzheimer's disease: a search for virus DNA by spot hybridisation. J Neurol Neurosurg Psychiatry. 1984; 47(10):1061-1065.
113. Roberts GW, Taylor GR, Carter GI, et al. Herpes simplex virus: a role in the aetiology of Alzheimer's disease? [letter]. J Neurol Neurosurg Psychiatry. 1986;49(2):216.
114. Pogo BG, Casals J, Elizan TS. A study of viral genomes and antigens in brains of patients with Alzheimer's disease. Brain. 1987;110(4):907-915.
115. Walker DG, O'Kusky JR, McGeer PL. In situ hybridization analysis for herpes simplex virus nucleic acids in Alzheimer disease. Alzheimer Dis Assoc Disord. 1989;3(3):123-131.
116. Kittur SD, Hoh JH, Kawas CH, et al. A molecular hybridization study for the presence of herpes simplex, cytomegalo-virus and Epstein-Barr virus in brain and blood of Alzheimer's disease patients. Arch Gerontol Geriatr. 1992;15(1):35-41.
117. Mann DM, Tinkler AM, Yates PO. Neurological disease and herpes simplex virus. An immunohistochemical study. Acta Neuropathol. 1983;60(1-2):24-28.
118. Jamieson GA, Maitland NJ, Wilcock GK, et al. Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. J Med Virol. 1991;33(4):224-227.
119. Jamieson GA, Maitland NJ, Craske J, et al. Detection of herpes simplex virus type 1 DNA sequences in normal and Alzheimer's disease brain using polymerase chain reaction. Biochem Soc Trans. 1991;19(2):122S.
120. Lin WR, Casas I, Wilcock GK, et al. Neurotropic viruses and Alzheimer's disease: a search for varicella zoster virus DNA by the polymerase chain reaction. J Neurol Neurosurg Psychiatry. 1997;62(6):586-589.
121. Itabashi S, Arai H, Matsui T, et al. Herpes simplex virus and risk of Alzheimer's disease [letter]. Lancet. 1997;349(9058): 1102.
122. Cheon MS, Bajo M, Gulesserian T, et al. Evidence for the relation of herpes simplex virus type 1 to Down syndrome and Alzheimer's disease. Electrophoresis. 2001;22(3): 445-448.
123. Lin W, Graham J, MacGowan S, et al. Alzheimer's disease, herpes virus in brain, apolipoprotein E4 and herpes labialis. Alzheimers Rep. 1998;1(3):173-178.
124. Renvoize EB, Awad IO, Hambling MH. A sero-epidemiological study of conventional infectious agents in Alzheimer's disease. Age Ageing. 1987;16(5):311-314.
125. Wozniak MA, Shipley SJ, Combrinck M, et al. Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients. J Med Virol. 2005;75(2): 300-306.
126. Berger M, Schroder B, Daeschlein G, et al. Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes. J Lab Clin Med. 2000;136(3): 194-200.
127. Dobrilovic N, Vadlamani L, Meyer M, et al. Chlamydia pneumoniae in atherosclerotic carotid artery plaques: high prevalence among heavy smokers. Am Surg. 2001;67(6): 589-593.
128. Sessa R, Di Pietro M, Schiavoni G, et al. Chlamydia pneumoniae in asymptomatic carotid atherosclerosis. Int J Immunopathol Pharmacol. 2006;19(1):111-118.
129. Hammond CJ, Hallock LR, Howanski RJ, et al. Immunohis-tological detection of Chlamydia pneumoniae in the Alzheimer's disease brain. BMC Neurosci. 2010;11:121. (doi:10.1186/1471-2202-11-121).
130. Johnson DL, Mahony JB. Chlamydophila pneumoniae PknD exhibits dual amino acid specificity and phosphory-lates Cpn0712, a putative type III secretion YscD homolog. J Bacteriol. 2007;189(21):7549-7555.
131. Little CS, Hammond CJ, MacIntyre A, et al. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging. 2004;25(4): 419-429.
132. Boelen E, Stassen FR, van der Ven AJ, et al. Detection of amyloid beta aggregates in the brain of BALB/c mice after Chlamydia pneumoniae infection. Acta Neuropathol. 2007;114(3):255-261.
133. King LS. Dr. Koch's postulates. J Hist Med Allied Sci. 1952;7(4):350-361.
134. Loeb MB, Molloy DW, Smieja M, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc. 2004;52(3): 381-387.
135. Nochlin D, Shaw CM, Campbell LA, et al. Failure to detect Chlamydia pneumoniae in brain tissues of Alzheimer's disease. Neurology. 1999;53(8):1888.
136. Gieffers J, Reusche E, Solbach W, et al. Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients. J Clin Microbiol. 2000;38(2):881-882.
137. Ring RH, Lyons JM. Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain. J Clin Microbiol. 2000;38(7):2591-2594.
138. Wozniak MA, Cookson A, Wilcock GK, et al. Absence of Chlamydia pneumoniae in brain of vascular dementia patients. Neurobiol Aging. 2003;24(6):761-765.
139. Taylor GS, Vipond IB, Paul ID, et al. Failure to correlate C. pneumoniae with late onset Alzheimer's disease. Neurology. 2002;59(1):142-143.
140. Bruunsgaard H, Ostergaard L, Andersen-Ranberg K, et al. Proinflammatory cytokines, antibodies to Chlamydia pneumoniae and age-associated diseases in Danish centenarians: is there a link? Scand J Infect Dis. 2002;34(7):493-499.
141. Yamamoto H, Watanabe T, Miyazaki A, et al. High prevalence of Chlamydia pneumoniae antibodies and increased high-sensitive C-reactive protein in patients with vascular dementia. J Am Geriatr Soc. 2005;53(4):583-589.
142. Dreses-Werringloer U, Bhuiyan M, Zhao Y, et al. Initial characterization of Chlamydophila (Chlamydia) pneumoniae cultured from the late-onset Alzheimer brain. Int J Med Microbiol. 2009;299(3):187-201.
143. Ecemiş T, Mavioglu H, Özkütük N, et al. Seroprevalance of Chlamydophila pneumoniae in patients with Alzheimer's disease and vascular dementia. J Neurol Sci Turk. 2010; 27(4):400-406.
144. Margos G, Vollmer SA, Ogden NH, et al. Population genetics, taxonomy, phylogeny and evolution of Borrelia burgdorferi sensu lato. Infect Genet Evol. 2011;11(7):1545-1563.
145. Duray PH, Steere AC. The spectrum of organ and systems pathology in human Lyme disease. Zentralbl Bakteriol Mik-robiol Hyg A. 1986;263(1-2):169-178.
146. MacDonald AB. Borrelia in the brains of patients dying with dementia [letter]. JAMA. 1986;256(16):2195-2196.
147. MacDonald AB, Miranda JM. Concurrent neocortical borre-liosis and Alzheimer's disease. Hum Pathol. 1987;18(7): 759-761.
148. MacDonald AB. Concurrent neocortical borreliosis and Alzheimer's disease. Ann N Y Acad Sci. 1988;539:468-470.
149. Meer-Scherrer L, Chang Loa C, Adelson ME, et al. Lyme disease associated with Alzheimer's disease. Curr Microbiol. 2006;52(4):330-332.
150. Miklossy J, Khalili K, Gern L, et al. Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. J Alzheimers Dis. 2004;6(6):639-649; discussion 673-81.
151. Miklossy J. Alzheimer's disease-a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. J Neuroinflammation. 2011;8:90. (doi:10.1186/1742-2094-8-90).
152. Miklossy J, Kis A, Radenovic A, et al. Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging. 2006;27(2):228-236.
153. Pappolla MA, Omar R, Saran B, et al. Concurrent neuroborreliosis and Alzheimer's disease: analysis of the evidence. Hum Pathol. 1989;20(8):753-757.
154. Gutacker M, Valsangiacomo C, Balmelli T, et al. Arguments against the involvement of Borrelia burgdorferi sensu lato in Alzheimer's disease. Res Microbiol. 1998;149(1):31-37.
155. Marques AR, Weir SC, Fahle GA, et al. Lack of evidence of Borrelia involvement in Alzheimer's disease [letter]. J Infect Dis. 2000;182(3):1006- 1007.
156. McLaughlin R, Kin NM, Chen MF, et al. Alzheimer's disease may not be a spirochetosis. Neuroreport. 1999; 10(7):1489-1491.
157. Galbussera A, Tremolizzo L, Isella V, et al. Lack of evidence for Borrelia burgdorferi seropositivity in Alzheimer disease [letter]. Alzheimer Dis Assoc Disord. 2008;22(3):308.
158. Riviere GR, Riviere KH, Smith KS. Molecular and immuno-logical evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol. 2002;17(2):113-118.
159. Ameriso SF, Fridman EA, Leiguarda RC, et al. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke. 2001;32(2):385-391.
160. Kowalski M, Rees W, Konturek PC, et al. Detection of Heli-cobacter pylori specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable angina. Dig Liver Dis. 2002;34(6): 398-402.
161. Malfertheiner MV, Kandulski A, Schreiber J, et al. Helico-bacter pylori infection and the respiratory system: a systematic review of the literature. Digestion. 2011;84(3):212-220.
162. Shaikh KH, Ahmed S, Ayyub M, et al. Association of Heli-cobacter pylori infection with idiopathic thrombocytopenic purpura. J Pak Med Assoc. 2009;59(10):660-663.
163. Rostami N, Keshtkar-Jahromi M, Rahnavardi M, et al. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. Am J Hematol. 2008;83(5): 376-381.
164. Campuzano-Maya G. Proof of an association between Heli-cobacter pylori and idiopathic thrombocytopenic purpura in Latin America. Helicobacter. 2007;12(3):265-273.
165. Kountouras J, Tsolaki M, Gavalas E, et al. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology. 2006;66(6):938-940.
166. Roubaud-Baudron C, Krolak-Salmon P, Quadrio I, et al. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiol Aging. 2012;33(5):1009.e11-1009.e19.
167. Kountouras J, Boziki M, Gavalas E, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol. 2009;256(5):758-767.
168. Kountouras J, Boziki M, Gavalas E, et al. Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn Behav Neurol. 2010;23(3):199-204.
169. Kountouras J, Tsolaki M, Boziki M, et al. Association between Helicobacter pylori infection and mild cognitive impairment. Eur J Neurol. 2007;14(9):976-982.
170. Kountouras J, Zavos C, Gavalas E, et al. Normal-tension glaucoma and Alzheimer's disease: Helicobacter pylori as a possible common underlying risk factor. Med Hypotheses. 2007;68(1):228-229.
171. Ge R, Sun X. The in vivo functions of a histidine-rich protein hpn in Helicobacter pylori: linking gastric and Alzheimer's diseases together? Med Hypotheses. 2011;77(5):788-790.
172. Shiota S, Murakami K, Yoshiiwa A, et al. The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. J Neurol. 2011;258(8):1460-1463.
173. Westermark GT, Westermark P. Prion-like aggregates: infectious agents in human disease. Trends Mol Med. 2010; 16(11):501-507.
174. Soto C, Estrada L, Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci. 2006;31(3):150-155.
175. Baskakov IV, Breydo L. Converting the prion protein: what makes the protein infectious. Biochim Biophys Acta. 2007;1772(6):692-703.
176. Moreno-Gonzalez I, Soto C. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol. 2011;22(5):482-487.
177. Shewmaker F, McGlinchey RP, Wickner RB. Structural insights into functional and pathological amyloid. J Biol Chem. 2011;286(19):16533-16540.
178. Kane MD, Lipinski WJ, Callahan MJ, et al. Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J Neurosci. 2000;20(10):3606- 3611.
179. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313(5794): 1781-1784.
180. Walker LC, Callahan MJ, Bian F, et al. Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides. 2002;23(7):1241-1247.
181. Eisele YS, Obermuller U, Heilbronner G, et al. Peripherally applied abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330(6006):980-982.
182. Bolmont T, Clavaguera F, Meyer-Luehmann M, et al. Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP x tau transgenic mice. Am J Pathol. 2007;171(6): 2012-2020.
183. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11(7):909-913.
184. Stöhr J, Watts JC, Mensinger ZL, et al. Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci U S A. 2012;109(27):11025-11030.
185. Riemenschneider M, Klopp N, Xiang W, et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology. 2004;63(2):364-366.
186. Gacia M, Safranow K, Styczynska M, et al. Prion protein gene M129 allele is a risk factor for Alzheimer's disease. J Neural Transm. 2006;113(11):1747- 1751.
187. Golanska E, Hulas-Bigoszewska K, Rutkiewicz E, et al. Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD. Neurology. 2004;62(2): 313-315.
188. Del Bo R, Scarlato M, Ghezzi S, et al. Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging. 2006;27(5): 770.e1-770.e5.
189. Dermaut B, Croes EA, Rademakers R, et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol. 2003;53(3):409-412.
190. Ahn K, Kim E, Kwon YA, et al. No association of prion protein gene polymorphisms with Alzheimer's disease in Korean population. Exp Mol Med. 2006;38(6):727-731.
191. Combarros O, Sanchez-Guerra M, Llorca J, et al. Polymorphism at codon 129 of the prion protein gene is not associated with sporadic AD. Neurology. 2000;55(4):593-595.
192. Infante J, Llorca J, Rodero L, et al. Polymorphism at codon 174 of the prion-like protein gene is not associated with sporadic Alzheimer's disease. Neurosci Lett. 2002;332(3): 213-215.
193. Jeong BH, Lee KH, Lee YJ, et al. Lack of association between PRNP 1368 polymorphism and Alzheimer's disease or vascular dementia. BMC Med Genet. 2009;10:32. (doi:10.1186/1471-2350-10-32).
194. Ohkubo T, Sakasegawa Y, Asada T, et al. Absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan. Ann Neurol. 2003;54(4):553-554.
195. Van Everbroeck B, Croes EA, Pals P, et al. Influence of the prion protein and the apolipoprotein E genotype on the Creutzfeldt-Jakob disease phenotype. Neurosci Lett. 2001;313(1-2):69-72.
196. Amouyel P, Vidal O, Launay JM, et al. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet. 1994; 344(8933):1315-1318.
197. Zerr I, Helmhold M, Poser S, et al. Apolipoprotein E pheno-type frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. Arch Neurol. 1996;53(12):1233-1238.
198. Friedland RP, May C, Dahlberg J. The viral hypothesis of Alzheimer's disease. Absence of antibodies to lentiviruses. Arch Neurol. 1990;47(2):177-178.
199. Strandberg T, Pitkala K, Eerola J, et al. Interaction of her-pesviridae, APOE gene, and education in cognitive impairment. Neurobiol Aging. 2005;26(7):1001-1004.
200. Lin WR, Wozniak MA, Cooper RJ, et al. Herpesviruses in brain and Alzheimer's disease. J Pathol. 2002;197(3): 395-402.
201. Hemling N, Roytta M, Rinne J, et al. Herpesviruses in brains in Alzheimer's and Parkinson's diseases. Ann Neurol. 2003;54(2):267-271.
202. Niehaus MD, Moore SR, Patrick PD, et al. Early childhood diarrhea is associated with diminished cognitive function 4 to 7 years later in children in a northeast Brazilian shantytown. Am J Trop Med Hyg. 2002;66(5):590-593.
203. Guerrant DI, Moore SR, Lima AA, et al. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil. Am J Trop Med Hyg. 1999;61(5):707-713.
204. Lorntz B, Soares AM, Moore SR, et al. Early childhood diarrhea predicts impaired school performance. Pediatr Infect Dis J. 2006;25(6):513-520.
205. Bronner MB, Knoester H, Sol JJ, et al. An explorative study on quality of life and psychological and cognitive function in pediatric survivors of septic shock. Pediatr Crit Care Med. 2009;10(6):636-642.
206. Semmler A, Hermann S, Mormann F, et al. Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation. 2008;15(5):38. (doi:10.1186/1742-2094-5-38).
207. Taccone FS, Su F, Pierrakos C, et al. Cerebral microcircula-tion is impaired during sepsis: an experimental study. Crit Care. 2010;14(4):R140. (doi:10.1186/cc9205).
208. Barichello T, Fortunato JJ, Vitali AM, et al. Oxidative variables in the rat brain after sepsis induced by cecal ligation and perforation. Crit Care Med. 2006;34(3):886-889.
209. Dal-Pizzol F, Ritter C, Cassol-Jr OJ, et al. Oxidative mechanisms of brain dysfunction during sepsis. Neurochem Res. 2010;35:1-12.
210. Chao CC, Hu S, Sheng WS, et al. Cytokine-stimulated astro-cytes damage human neurons via a nitric oxide mechanism. Glia. 1996;16(3):276-284.
211. Chung KK, David KK. Emerging roles of nitric oxide in neurodegeneration. Nitric Oxide. 2010;22(4):290-295.
212. Culbert AA, Skaper SD, Howlett DR, et al. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2006;281(33):23658-23667.
213. De Paola M, Buanne P, Biordi L, et al. Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary cultures. Neuroimmunomodulation. 2007;14(6): 310-316.
214. Moreno B, Jukes JP, Vergara-Irigaray N, et al. Systemic inflammation induces axon injury during brain inflammation. Ann Neurol. 2011;70(6):932-942.
215. Semmler A, Frisch C, Debeir T, et al. Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp Neurol. 2007;204(2):733-740.
216. Iwashyna TJ, Ely EW, Smith DM, et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787-1794.
217. Carter MW, Porell FW. Vulnerable populations at risk of potentially avoidable hospitalizations: the case of nursing home residents with Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2005;20(6):349-358.
218. Perls TT, Herget M. Higher respiratory infection rates on an Alzheimer's special care unit and successful intervention. J Am Geriatr Soc. 1995;43(12):1341-1344.
219. Heun R, Schoepf D, Potluri R, et al. Alzheimer's disease and co-morbidity: increased prevalence and possible risk factors of excess mortality in a naturalistic 7-year follow-up [published online ahead of print September 14, 2011]. Eur Psychiatry. (doi:10.1016/j.eurpsy.2011.06.001).
220. Natalwala A, Potluri R, Uppal H, et al. Reasons for hospital admissions in dementia patients in Birmingham, UK, during 2002-2007. Dement Geriatr Cogn Disord. 2008;26(6): 499-505.
221. Albert SM, Costa R, Merchant C, et al. Hospitalization and Alzheimer's disease: results from a community-based study. J Gerontol A Biol Sci Med Sci. 1999;54(5):M267-M271.
222. Oria RB, Patrick PD, Zhang H, et al. APOE4 protects the cognitive development in children with heavy diarrhea burdens in northeast Brazil. Pediatr Res. 2005;57(2):310-316.
223. Burgos JS, Ramirez C, Sastre I, et al. ApoE4 is more efficient than E3 in brain access by herpes simplex virus type 1. Neuroreport. 2003;14(14):1825- 1827.
224. Burt TD, Agan BK, Marconi VC, et al. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A. 2008;105(25):8718-8723.
225. Kuhlmann I, Minihane AM, Huebbe P, et al. Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis. 2010;9:8. (doi:10.1186/1476-511X-9-8).
226. Jayasuriya AN, Itzhaki RF, Wozniak MA, et al. Apolipopro-tein E-epsilon 4 and recurrent genital herpes in individuals co-infected with herpes simplex virus type 2 and HIV. Sex Transm Infect. 2008;84(7):516-517.
227. Wang H, Christensen DJ, Vitek MP, et al. APOE genotype affects outcome in a murine model of sepsis: implications for a new treatment strategy. Anaesth Intensive Care. 2009;37(1):38-45.
228. Chen JH, Lin KP, Chen YC. Risk factors for dementia. J Formos Med Assoc. 2009;108(10):754-764.
229. Mortimer JA. The Nun Study: risk factors for pathology and clinical-pathologic correlations. Curr Alzheimer Res. 2012; 9(6):621-627.
230. Krieger N, Chen JT, Waterman PD, et al. Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures-The Public Health Disparities Geocoding Project. Am J Public Health. 2003;93(10):1655-1671.
231. Malaty HM, Logan ND, Graham DY, et al. Helicobacter pylori infection in preschool and school-aged minority children: effect of socioeconomic indicators and breast-feeding practices. Clin Infect Dis. 2001;32(10):1387-1392.
232. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10(9):819-828.
233. Bhat NR. Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators. J Neurochem. 2010;115(3):551-562.
234. Wang Y, Beydoun MA. The obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6-28.
235. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection [published online ahead of print May 1, 2012]. Int J Obes (Lond). (doi:10.1038/ijo.2012.62).
236. Schooling CM, Jones HE, Leung GM. Lifecourse infectious origins of sexual inequalities in central adiposity. Int J Epidemiol. 2011;40(6):1556-1564.
237. Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med (Maywood). 2010;235(12): 1412-1424.
238. Wojtowicz WM, Farzan M, Joyal JL, et al. Stimulation of enveloped virus infection by beta-amyloid fibrils. J Biol Chem. 2002;277(38):35019-35024.
239. Bowman GL, Kaye JA, Moore M, et al. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68(21):1809-1814.
240. Skoog I, Wallin A, Fredman P, et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology. 1998;50(4):966-971.
241. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337-352.
242. Biron KE, Dickstein DL, Gopaul R, et al. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One. 2011;6(8):e23789. (doi:10.1371/journal. pone.0023789).
243. Caserta MT, Caccioppo D, Lapin GD, et al. Blood-brain barrier integrity in Alzheimer's disease patients and elderly control subjects. J Neuropsychiatry Clin Neurosci. 1998; 10(1):78-84.
244. Frolich L, Kornhuber J, Ihl R, et al. Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG. Eur Arch Psychiatry Clin Neurosci. 1991;240(6):363-366.
245. Schlageter NL, Carson RE, Rapoport SI. Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography. J Cereb Blood Flow Metab. 1987;7(1):1-8.
246. Honjo K, van Reekum R, Verhoeff NP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement. 2009;5(4): 348-360.
247. Fredricks DN, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. Clin Microbiol Rev. 1996;9(1):18-33.
248. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.